Calithera Biosciences – $80 Million Shelf-Takedown Offering

Palo Alto – April 7, 2017 – Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase an additional 1,024,500 shares. 

Calithera, which is headquartered in South San Francisco and trades on The NASDAQ Global Select Market as "CALA," is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. 

Cooley has worked with Calithera since its formation and advised the company on its $80 million IPO in October 2014.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Barbara Kosacz Partner, Palo Alto
John McKenna Partner, Palo Alto
Seth Gottlieb Partner, Palo Alto
David Ambler Associate, Palo Alto
Kate Nichols Associate, Palo Alto
Natasha Leskovsek Partner, Washington, DC
Susan Cooper Philpot Partner, San Francisco
Mark Windfeld-Hansen Partner, Palo Alto
Francis Wheeler Partner, Colorado